2.Lieberman, JA, Stroup, TS, McEvoy, JP, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. Epub 2005 Sep 19.
3.McEvoy, JP, Lieberman, JA, Stroup, TS, et al.Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;16(4):600–610.
4.Stroup, TS, Lieberman, JA, McEvoy, JP, et al.Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611–622.
5.Stroup, TS, McEvoy, JP, Swartz, MS, et al.The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29(1):15–31.
6.Citrome, L, Blonde, L, Damatarca, C. Metabolic issues in patients with severe mental illness. South Med J. 2005;98(7):714–720.
7.Stroup, TS (2004) Antipsychotic drug treatment of schizophrenia: update on the CATIE trial. In: NCDEU Abstracts from the 44th Annual Meeting, June 1-4, 2004, Phoenix, Arizona. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health, Bethesda, MD.
8.McEvoy, JP, Meyer, JM, Goff, DC, et al.Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19–32. Epub 2005 Aug 30.
9.Nasrallah, HA, Meyer, JM, Goff, DC, et al.Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006 Jul 31; [Epub ahead of print].
10.Lehman, AF, Lieberman, JA, Dixon, LB, et al.Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56.
11.Swartz, MS, Perkins, DO, Stroup, TS, McEvoy, JP, Nieri, JM, Haak, DC. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull. 2003;29(1):33–43.
12.Citrome, L, Stroup, TS: Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract. 2006;60(8):933–940.
1.Dolder, CR, Lacro, JP, Jeste, DV. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosomatics. 2003;65:156–162.
2.Dolder, CR, Lacro, JP, Leckband, S, Jeste, DV. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol. 2003;23(4):389–399.
3.Wendling. Clin Psychiatry News. 2005;33(10):1.